Sanofi SA vs Eli Lilly and: why the prices moved differently

• ▼

  Amlitelimab discontinued for atopic dermatitis Sanofi stopped developing amlitelimab for atopic dermatitis after a pipeline review found it was no better than current treatments. This removes a key future immunology drug, which can lower investor expectations for growth and weigh on the stock price.

  This is a major pipeline failure that directly affects Sanofi's future revenue prospects.

• ▼

  Advertising watchdog questions Dupixent claims The National Advertising Division recommended Sanofi modify or stop some Dupixent TV and prescriber claims about long-lasting clearer skin and fast itch relief. This could limit marketing and slow sales of Sanofi's biggest drug, a negative for the stock.

  Regulatory scrutiny of Dupixent marketing could hurt sales of Sanofi's top revenue driver.

• ▲

  New Phase 1 trial for oral STAT6 degrader Sanofi began a Phase 1 trial of an oral STAT6 degrader for type 2 inflammatory diseases, triggering a $10 million milestone to partner Nurix. This early-stage asset shows pipeline progress and could become a future growth driver, supporting the stock.

  It demonstrates continued pipeline advancement despite the amlitelimab setback.

• ▲

  High dividend yield and buyback support valuation Sanofi offers a 5.6% dividend yield and completed a €1 billion buyback, with total shareholder yield near 11%. Dupixent sales grew 31% and the stock trades at a low forward P/E of 9, making it attractive to income and value investors.

  These capital returns and cheap valuation provide a floor for the stock price.

Based on 7 stories →

• ▲

  New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

  This is a key positive fundamental driver showing Sanofi's growth diversification.

• ▲

  Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

  This major partnership expansion is a new positive catalyst for Sanofi's future growth.

• ▼

  Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

  These competitive losses directly threaten Sanofi's existing product revenue.

• ◆

  Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

  This strategic divestment has ambiguous implications for Sanofi's future earnings.

Based on 8 stories →

• ▲

  EU approval of MenQuadfi for infants Sanofi won EU approval to use its MenQuadfi vaccine in infants as young as six weeks, opening a new market. This should boost vaccine sales and strengthen Sanofi's pediatric portfolio, supporting the stock price.

  This is a new regulatory win that directly expands Sanofi's vaccine market and revenue potential.

• ▲

  Novavax partnership advances with milestones Sanofi's partnership with Novavax is progressing, with a Phase 3 COVID/flu combo study planned and milestone payments ahead. Sanofi will lead commercial launches of Nuvaxovid, adding to its vaccine business and future revenue.

  This shows Sanofi's collaboration is moving forward, with potential milestone income and expanded commercial reach.

• ▼

  Permanent halt of infant RSV vaccine trial Sanofi permanently stopped its Phase 3 RSV vaccine trial in infants after an infant death, raising safety and regulatory concerns. This removes a potential future product and may hurt Sanofi's reputation in pediatric vaccines, weighing on the stock.

  This is a major pipeline setback with reputational and regulatory implications that could lower investor confidence.

• ▼

  Competition heats up from AbbVie and Moderna AbbVie is buying Apogee to get a drug that could rival Sanofi's top-selling Dupixent, while Moderna won FDA approval for the first mRNA flu shot, challenging Sanofi's flu vaccine franchise. Both threaten key Sanofi products.

  These are new competitive threats that could pressure Sanofi's sales in two major areas: immunology and flu vaccines.

Based on 6 stories →

• ▲

  Q2 earnings beat and raised 2026 guidance Sanofi reported Q2 sales up 17.8% and raised its 2026 outlook, with Dupixent sales jumping 37.6% to €5.2 billion. This strong performance and confident guidance signal accelerating growth, which should lift investor confidence and support a higher share price.

  This is the most significant new event, directly showing Sanofi's financial health and future prospects.

• ▼

  Amlitelimab development halted for atopic dermatitis Sanofi discontinued amlitelimab for moderate-to-severe atopic dermatitis, a key pipeline candidate, due to insufficient efficacy and safety data. This removes a potential growth driver and may hurt sentiment, as investors had high hopes for the drug in a large market.

  This is a major pipeline setback that could negatively impact future revenue expectations.

• ▲

  Dupixent partner Regeneron beats estimates Regeneron's strong quarterly results, driven by Dupixent sales up 38% to $6 billion, confirm robust demand for Sanofi's top-selling drug. As Sanofi records these sales, the beat reinforces confidence in Dupixent's growth trajectory and Sanofi's earnings power.

  This provides independent validation of Dupixent's blockbuster performance, a key value driver for Sanofi.

• ▲

  Aqemia AI collaboration expands with new target Sanofi expanded its AI-driven drug discovery partnership with Aqemia, nominating a new target and potentially paying up to $140 million in milestones. This strengthens Sanofi's early-stage pipeline and shows commitment to innovative technologies, which could yield future blockbuster drugs.

  This highlights Sanofi's investment in cutting-edge R&D, supporting long-term growth prospects.

Based on 6 stories →

• ▲

  FDA approves Sarclisa Escena on-body injector The FDA approved subcutaneous Sarclisa Escena for all multiple myeloma uses, the first anticancer treatment given via on-body injector. It cuts treatment time and infusion reactions, which can lift sales and strengthen Sanofi's cancer franchise.

  This is a new regulatory approval that expands a key product's use and could drive future revenue.

• ▲

  Nexviazyme hits all goals in infant Pompe disease trial Sanofi's Nexviazyme met all endpoints in a phase 3 study for infants with infantile-onset Pompe disease, supporting a US label extension filing later in 2026. Success in a rare disease with few options adds a new growth driver.

  Positive late-stage trial data for an existing drug opens a new patient population and revenue stream.

• ▲

  WAYRILZ positioned in fast-growing AIHA market A market report projects 14.4% annual growth for warm autoimmune hemolytic anemia treatments through 2036, with no approved therapies yet. Sanofi's WAYRILZ is a key late-stage candidate, giving it a large untapped opportunity if approved.

  Highlights a new market opportunity for a Sanofi pipeline drug, supporting long-term growth prospects.

• ▼

  UBS cautious on Sanofi within favored pharma sector UBS likes European pharma as a safer bet than AI but is more cautious on Sanofi, preferring AstraZeneca and Roche. This relative caution may steer some investor money away from Sanofi shares, limiting upside versus peers.

  Analyst preference can influence capital flows and relative stock performance.

Based on 6 stories →

• ▲

  Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

  Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

• ▲

  Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

  New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

• ▼

  EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

  Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

• ▼

  AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

  Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

Based on 10 stories →

• ▲

  Foundayo and Zepbound data widen Lilly's obesity lead New analyses showed higher-dose Zepbound beat high-dose Wegovy on weight loss, and oral Foundayo beat oral semaglutide on weight and blood sugar. Guggenheim raised its Foundayo sales forecasts and price target. These results support future sales and keep Lilly ahead in the obesity market.

  Obesity is Lilly's biggest profit engine, and these data points directly support its pricing power and market share.

• ▲

  FDA approvals and pipeline wins broaden Lilly beyond obesity Lilly won FDA approvals for Olumiant in kids with severe alopecia, once-weekly insulin Onswik, and Jaypirca as a first-line leukemia treatment. It also got Breakthrough status for a pancreatic cancer drug and positive eczema trial results. These add new revenue streams and reduce reliance on weight-loss drugs.

  Diversification lowers the risk of depending on one drug class and adds fresh sales growth.

• ▲

  Lilly keeps buying and partnering to fuel future growth Lilly signed a deal with InnoCare worth up to $3.35 billion, expanded its Gate Bioscience collaboration past $870 million, and opened AI drug-discovery models to biotech. The CEO said more large acquisitions are coming, funded by obesity-drug cash flow. This builds the pipeline for years ahead.

  These deals show Lilly is reinvesting its profits into new science, which supports long-term growth.

• ▼

  Competition and legal setbacks are real counterweights Novo Nordisk data showed its Ozempic had a 6% lower heart-risk than Lilly's Mounjaro, and a jury ordered Lilly to pay about $115 million to Nektar in a contract dispute. A Foghorn cancer collaboration was also halted. These are small versus Lilly's size but show it is not unbeatable.

  It gives the fair picture that Lilly faces genuine competitive and legal headwinds, not just good news.

Based on 24 stories →

• ▲

  Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity leadership.

  This is a new update on Foundayo's market share, directly driving revenue expectations.

• ▲

  Lilly raises 2026 revenue guidance to $85-87B Lilly increased its full-year revenue outlook, reflecting strong demand for its obesity and diabetes drugs. Higher guidance signals management confidence and typically lifts investor sentiment, pushing the stock up.

  Guidance raise is a new, concrete financial update that affects valuation.

• ▲

  Retatrutide shows 20.8% weight loss in Phase 3 Lilly's experimental triple agonist retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with strong blood sugar reductions. This bolsters Lilly's pipeline and future growth prospects beyond current drugs.

  New clinical data on a key pipeline asset strengthens long-term growth story.

• ▲

  Foundayo cuts cardiovascular risk in large trial In a major Phase 3 trial, Foundayo reduced the risk of heart attacks, strokes, and death compared to insulin in diabetes patients. This could expand the drug's use and strengthen its competitive position, supporting sales.

  New trial results add a cardiovascular benefit, potentially widening Foundayo's label and demand.

• ▲

  Jaypirca approved as first-line CLL/SLL treatment The FDA approved Lilly's Jaypirca for previously untreated chronic lymphocytic leukemia, based on a trial showing significantly improved progression-free survival. This expands Lilly's oncology revenue and diversifies beyond obesity.

  New regulatory approval opens a new revenue stream and reduces reliance on GLP-1 drugs.

Based on 6 stories →

• ▲

  FDA approves new breast cancer combo The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutated breast cancer, based on a trial where the combo doubled progression-free survival versus Inluriyo alone. This expands Lilly's oncology offerings and adds a new revenue stream, helping diversify beyond obesity drugs.

  New approval directly boosts Lilly's oncology business and revenue potential.

• ▲

  Lilly breaks ground on $6.5B Houston plant Lilly started building a $6.5 billion manufacturing site in Houston to produce active ingredients for its medicines, including the oral obesity drug Foundayo. This is part of a $50 billion U.S. investment to expand capacity and secure supply for future growth.

  Major capital investment supports long-term production capacity and supply chain.

• ▼

  Novo's CagriSema beats Zepbound in head-to-head trial In a phase 3 trial, Novo's CagriSema helped patients lose 12.4% of their weight over 60 weeks, compared to 9.1% for Lilly's Zepbound. This suggests a competitive threat in the obesity market, potentially slowing Lilly's market share gains if CagriSema wins approval.

  Direct competitive trial result could pressure Lilly's obesity franchise.

• ▲

  FDA approves once-weekly insulin Onswik The FDA approved Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes, which cuts injections from daily to weekly. This strengthens Lilly's diabetes portfolio and offers a more convenient option, potentially capturing market share from daily insulins.

  New product approval expands diabetes franchise and addresses patient convenience.

Based on 14 stories →

• ▲

  Foundayo grabs 30% of new US oral weight-loss patients Lilly's new obesity pill Foundayo has captured over 30% of new US patients starting oral weight-loss medicines, up from almost nothing. Novo's Wegovy pill once held about 90% of that market. This shows Lilly is winning real prescriptions, not just headlines, which supports future sales.

  Concrete evidence that Lilly's newest product is taking market share, a key growth driver.

• ▲

  Citi raises Lilly target to Street-high $1,600 Citi lifted its Lilly price target to $1,600, implying about 45% upside, even after the stock fell 8% in a month. The analyst points to Lilly's dominance in obesity prescriptions, Foundayo's prescriber growth, and retatrutide's strong trial results. This boosts investor confidence.

  A major analyst upgrade directly addresses why the stock could move higher despite recent weakness.

• ▲

  Lilly completes AtaiBeckley deal for depression drug Lilly closed its acquisition of AtaiBeckley, adding BPL-003, a rapid-acting treatment for depression that resists standard therapy. This expands Lilly's neuroscience pipeline beyond obesity, using its cash to plant seeds for future growth. It reduces reliance on weight-loss drugs.

  Shows Lilly is actively diversifying into new treatment areas, a strategic positive.

• ▲

  New data and deals bolster pipeline at EASD and beyond Lilly will present strong trial data for retatrutide, Foundayo, and eloraTZP at a major diabetes conference. It also signed new research deals with QurCan and Twist Bioscience. These moves strengthen Lilly's pipeline and technology, supporting long-term growth even if they don't boost sales immediately.

  Highlights ongoing pipeline progress and partnerships that underpin future revenue.

Based on 13 stories →

• ▲

  Lilly hits $1 trillion market cap on obesity drug strength Lilly crossed $1 trillion in market value, with Q2 revenue up 47.7% and Mounjaro sales up 91%. The obesity franchise and expanded access are powering growth, and analysts see more upside.

  This milestone reflects the scale of Lilly's success and investor confidence, directly answering why the stock is moving.

• ▲

  J.P. Morgan raises estimates on obesity drug growth J.P. Morgan lifted 2027 revenue and EPS forecasts, keeping an Overweight rating and $1,400 target. It expects incretin sales to exceed $100 billion by 2030, driven by Zepbound, Mounjaro, and Foundayo.

  Analyst upgrades signal growing confidence in Lilly's long-term growth, a key driver of stock movement.

• ▲

  Lilly launches Foundayo in UK, first European market Lilly launched its oral weight-loss pill Foundayo in the UK, the first European market. The pill costs £100-£120 per month, much less than injections, potentially widening access and boosting sales.

  This is a concrete step in expanding Lilly's obesity franchise globally, directly supporting future revenue growth.

• ▲

  Lilly builds neuroscience as new growth driver Neuroscience revenue grew 32% to $811 million in H1 2026, led by Kisunla. Acquisitions like AtaiBeckley and Centessa add pipeline assets, diversifying beyond obesity and reducing reliance on GLP-1 drugs.

  This shows Lilly's efforts to create a second growth engine, which could sustain long-term growth and attract investors.

Based on 11 stories →

• ▲

  FDA expands Mounjaro label to cut heart risks The FDA approved Mounjaro to lower the risk of heart attacks, strokes and heart-related death in high-risk type 2 diabetes patients. This makes the drug useful for more people, supporting sales and pricing power, though it also increases pressure on manufacturing capacity and insurance coverage.

  A new regulatory approval directly expands the market for Lilly's biggest drug.

• ▲

  Taltz plus Zepbound shows durable one-year benefit Phase 3b trials showed combining Taltz and Zepbound helped patients with psoriatic disease and obesity achieve clearer skin and more weight loss than Taltz alone after a year. This supports using Lilly drugs together, which could boost sales across both products.

  New clinical data supports broader use of two Lilly drugs together.

• ▲

  Lilly buys Merida Biosciences for up to $2.875 billion Lilly agreed to buy Merida Biosciences for up to $2.875 billion, gaining an early-stage immunology drug for Graves' disease and thyroid eye disease. This uses cash from Lilly's obesity franchise to diversify into new treatment areas, though the drug is still years from market.

  A major acquisition shows Lilly using its cash to build new growth beyond weight-loss drugs.

• ▼

  Novo launches oral Wegovy in Germany as competition builds Novo Nordisk launched its Wegovy pill in Germany, the EU's largest drug market, and expects pills to take over a third of GLP-1 use by 2030. Lilly's Foundayo pill is in Britain and targeting 40+ markets, so this is a real race for the oral obesity market.

  A direct competitor's launch in a key market threatens Lilly's share of the growing oral GLP-1 market.

Based on 8 stories →

• ▲

  Zepbound shown to cut healthcare costs in older adults A real-world study found Zepbound users over 55 had up to 38% lower healthcare costs, with savings reaching $607 per patient per month by 12 months. This evidence could persuade Medicare and insurers to cover obesity drugs, supporting demand.

  This new study directly addresses payer resistance, a key risk, by showing cost savings that could expand coverage and demand.

• ▼

  14% of US employers to drop obesity drug coverage by 2027 A survey shows about 14% of US employers plan to end GLP-1 coverage by 2027 due to rising costs, with the share covering obesity drugs already falling from 72% to 60%. This could reduce Zepbound prescriptions and slow US sales growth.

  This is a new, concrete threat to demand from a major payer group, directly countering the positive coverage narrative.

• ▲

  FDA clears Lilly-Roche Alzheimer's blood test The FDA cleared the Elecsys pTau217 blood test, developed with Roche, as the first single-biomarker test to rule in or out Alzheimer's amyloid pathology. This could expand diagnosis and boost the market for Lilly's Alzheimer's drug donanemab.

  This new approval opens a path to wider Alzheimer's diagnosis and treatment, a potential new growth area beyond GLP-1 drugs.

• ▲

  Oncology portfolio grows 11%, diversifying beyond GLP-1 Lilly's oncology revenue rose 11% to $4.84 billion in the first half, with newer drugs like Jaypirca up 66% and Inluriyo contributing $110 million. This shows Lilly is building a second growth engine, reducing reliance on obesity drugs.

  This new data highlights a broadening revenue base, which is important for long-term growth and risk reduction.

Based on 15 stories →

• ▲

  UK approves Foundayo for weight loss and diabetes Britain cleared Lilly's once-daily weight-loss pill Foundayo for both obesity and type 2 diabetes, the first European approval. A pill is easier for patients than injections, so it opens a new market and widens Lilly's lead over Novo's rival pill.

  New regulatory approval expands Lilly's addressable market and competitive position.

• ▲

  Lilly adds Alzheimer's and ion channel deals Lilly bought rights to an early-stage Alzheimer's drug for $10 million upfront (up to $1 billion more if it works) and teamed up with OmniAb on an ion channel program worth up to $370 million. These small bets refill the pipeline beyond weight-loss drugs.

  New deals diversify Lilly's pipeline and reduce reliance on GLP-1s.

• ▲

  Lilly partners on RNA vaccines Lilly signed a research and licensing deal with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases, with options for two more targets. It is an early-stage move into a new treatment area, using Lilly's cash to plant seeds for future growth.

  New collaboration expands Lilly's technology base into vaccines.

• ▼

  Novo CEO says obesity market won't be winner-take-all Novo Nordisk's chief said the obesity market will split among many players, like different soda brands, rather than one winner. Novo's oral Wegovy already holds 90% of the oral GLP-1 market. This is a reminder that Lilly's dominance may face limits as competition grows.

  A real counterweight: competition could cap Lilly's long-term market share.

Based on 12 stories →

• ▲

  UK approves Foundayo, first market outside US Britain's regulator cleared Lilly's once-daily weight-loss pill Foundayo, the first approval outside the US. This opens a new market for a pill version of its obesity drug, which could reach patients who dislike injections. It is not yet sold through the NHS while cost regulators review it.

  A brand-new regulatory approval expands Lilly's addressable market beyond the US.

• ▲

  Amazon and CVS widen cheap access to Lilly drugs Amazon Pharmacy will offer Lilly's Zepbound pen and Foundayo pill to Medicare patients for $50 a month, and CVS expanded its weight-management program with Lilly, adding app-based access and $29 clinic visits. Easier, cheaper access should lift prescription volumes.

  New distribution deals directly increase how many patients can get Lilly's drugs.

• ▲

  Lilly sues sellers of unapproved retatrutide Lilly filed six lawsuits against businesses selling unapproved versions of retatrutide, its experimental obesity drug, and has referred over 200 parties to authorities. This protects the future franchise from unsafe copycats and keeps the market ready for the real drug when approved.

  Legal action defends a key future growth driver from illicit competition.

• ▲

  Analysts raise targets on international obesity opportunity BofA lifted its Lilly price target to $1,344 and said overseas obesity sales could eventually beat the US, with most Foundayo peak sales expected abroad. Other banks also raised targets after strong Q2 results. This reflects growing confidence in Lilly's global growth runway.

  Analyst upgrades signal that the market sees more upside from international expansion.

Based on 19 stories →

• ▲

  Q2 beat and raised guidance Lilly reported Q2 revenue of $22.97 billion, up 47.7%, and adjusted EPS of $8.38, beating estimates by 27%. Management raised full-year revenue guidance to $85–$87 billion and EPS to $36.25. The stock jumped as much as 7% on the news, reflecting strong demand for its obesity and diabetes drugs.

  This is the core new event that directly answers why LLY is moving right now.

• ▲

  Mounjaro and Zepbound sales surge Mounjaro sales jumped 91% to $9.94 billion and Zepbound brought in $4.93 billion, together 65% of total revenue. This shows Lilly's GLP-1 franchise is still growing rapidly, driving the earnings beat and giving confidence that demand remains strong despite competition.

  It explains the fundamental driver behind the beat-and-raise and the stock's move.

• ▲

  Novo Nordisk's setback boosts Lilly's competitive edge Novo Nordisk's next-generation obesity drug CagriSema fell short of Lilly's Zepbound in blood sugar control, and Novo guided to a sales decline and cut 9,000 jobs. This strengthens Lilly's position as the clear leader in the obesity market, which supports its pricing power and long-term growth.

  It highlights a key competitive shift that benefits Lilly and is new information.

• ▲

  Retatrutide filing planned for early 2027 Lilly plans to file for approval of its next-generation obesity drug retatrutide in early 2027. The drug helped patients lose over 20% of body weight and could also treat sleep apnea and reduce heart risk. Analysts see it as a future growth driver, though it won't contribute revenue until after 2027.

  It is a new pipeline update that reinforces Lilly's long-term growth story.

Based on 10 stories →

• ▲

  Q1 revenue surges 55.5% on Foundayo launch Lilly's first-quarter revenue jumped 55.5% to $19.8 billion, beating estimates, as new oral GLP-1 Foundayo and strong Mounjaro and Zepbound sales drove growth. Management raised full-year guidance, and an analyst set a $1,365 price target, reinforcing confidence in Lilly's earnings power.

  This shows the core financial engine behind Lilly's stock and why analysts remain bullish.

• ▲

  Retatrutide Phase 3 success, FDA filing planned Lilly's next-generation obesity drug retatrutide cut weight by up to 22.6% in Phase 3 trials, with a planned FDA submission in early 2027. This strengthens Lilly's future obesity franchise, though a slight imbalance in serious heart events bears watching.

  It confirms a major future growth driver and addresses the earlier delay, showing the pipeline is back on track.

• ▲

  Lilly expands US manufacturing with Resilience Lilly and Resilience are investing $750 million to expand U.S. production of the KwikPen injectable device, creating 400 jobs and boosting supply capacity for diabetes and obesity medicines. This helps ensure Lilly can meet soaring demand and reduces reliance on foreign manufacturing.

  It directly addresses supply constraints that could limit growth and shows Lilly investing in its core business.

• ▲

  Lilly joins Illumina's AI drug discovery alliance Lilly became a foundational participant in Illumina's Billion Cell Atlas, gaining access to massive genetic data to speed AI-driven drug discovery. This long-term move could help diversify Lilly's pipeline beyond GLP-1 drugs and keep it at the forefront of biotech innovation.

  It signals a strategic push into next-generation technology that could yield new drugs and reduce reliance on one franchise.

Based on 10 stories →

• ▲

  Lilly to buy AtaiBeckley for up to $3.8B Lilly agreed to pay $2.8 billion upfront, plus up to $1 billion more if milestones are met, for AtaiBeckley and its experimental psychedelic depression treatment. It uses Lilly's cash to add a new growth area beyond weight-loss drugs, though the upfront cost is real.

  This is the period's biggest new deal and shows how Lilly is spending its obesity-drug profits to diversify.

• ▼

  Retatrutide approval filing delayed to early 2027 Lilly pushed back its filing for next-generation obesity drug retatrutide because it needs more manufacturing and quality-control data for regulators. The drug still worked well in trials, but the delay means a key future growth driver arrives later than expected.

  This is the main new negative and directly affects Lilly's next big obesity-drug opportunity.

Based on 6 stories →

• ▼

  Germany's cost reform raises rebates, Lilly to scale back manufacturing Germany passed a law forcing drugmakers to pay higher rebates, aiming to cut €16 billion in health costs. Lilly's CEO said the company will scale back manufacturing plans there, a real headwind for its European business and investment.

  A concrete regulatory setback that could hurt Lilly's sales and expansion in a major market.

• ▲

  Lilly acquires AtaiBeckley for up to $3.8 billion Lilly is buying psychedelic drugmaker AtaiBeckley for about $2.8 billion upfront plus up to $1 billion in milestones. This adds a promising treatment for resistant depression to Lilly's pipeline, showing it is using its cash to expand beyond weight-loss drugs.

  A new strategic move that broadens Lilly's pipeline and signals long-term growth ambitions.

• ▼

  Novo Nordisk wins EU approval for oral Wegovy Novo Nordisk got EU clearance for the first oral GLP-1 pill for weight management, giving patients a pill option alongside injections. This intensifies competition for Lilly's obesity drugs in Europe, where pill preference could shift market share.

  A direct competitive threat in the key obesity market that could pressure Lilly's growth.

Based on 6 stories →

• ▲

  JPMorgan raises price target to $1,400, stock hits record JPMorgan lifted its LLY target from $1,300 to $1,400 and reiterated overweight, citing strong demand for Mounjaro and Zepbound. The stock hit an all-time high above $1,200, with market cap surpassing $1.1 trillion. Analyst expects Q2 earnings to beat consensus.

  This is a new analyst action that directly boosted the stock and reflects confidence in future growth.

• ▲

  Lilly presents Alzheimer's data at AAIC 2026 Lilly will present 16 abstracts at the Alzheimer's conference, including new data on its Kisunla treatment and a P-tau217 blood test that could simplify diagnosis. This advances its pipeline beyond obesity, offering another long-term growth driver.

  This is a new pipeline update that shows Lilly's broader research strength beyond weight-loss drugs.

• ▲

  Canada backs Lilly's eczema drug Ebglyss Canada's drug agency gave a positive recommendation for Lilly's eczema treatment Ebglyss, which could lead to public reimbursement and wider patient access. Ebglyss is already approved in Canada and other countries, and this expands its reach.

  This is a new regulatory win that broadens Lilly's revenue base beyond obesity and diabetes.

Based on 15 stories →

• ▲

  Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

  This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

• ▲

  Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

  New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

• ▲

  Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

  Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

• ▲

  Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

  Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

Based on 9 stories →